Comparison of 99mTc-MIBI scintigraphy and sentinel node biopsy in the detection of occult lymph node metastases from cutaneous melanoma

European Journal of Dermatology

Volumn 13, Issue 5, 2003, Pages 449-454

  Alonso, Omar ^a   Martínez, Miguel ^a   Delgado, Lucía ^a   Lago, Graciela ^a   Juri, Cecilia ^a   Borges, Alejandra Larre ^a   Lopes De Amorim, María C ^a   De Boni, Daniela ^a,b   Espasandín, José ^b   Priario, Julio ^a  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b National Institute of Oncology   (Uruguay)

Author keywords

99mTc MIBI; Lymph node metastases; Melanoma; Scintigraphy; Sentinel node

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; MELANOMA; SCINTIGRAPHY; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SKIN CARCINOMA; STATISTICAL SIGNIFICANCE; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI;

EID: 0142184342     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. st century. CA Cancer J Clin 2000; 50: 215-36.
2. Chao C, McMasters KM. Update on the use of sentinel node biopsy in patients with melanoma: who and how. Curr Opin Oncol 2002; 14: 217-20.
3. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9.
4. Dubois RW, Swetter SM, Atkins M, et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol 2001; 137: 1217-24.
5. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
6. Voit C, Schoengen A, Schwurzer-Voit M, et al. The role of ultrasound in detection and management of regional disease in melanoma patients. Semin Oncol 2002; 29: 353-60.
7. Swetter SM, Carroll LA, Johnson DL, Segall GM. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 2002; 9: 646-53.
8. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12: 479-90.
9. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron Emissian tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17: 1508-15.
10. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomagraphy scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001; 19: 2674-8.
11. Kokoska MS, Olson G, Kelemen PR, et al. The use of lymphoscintigraphy and PET in the management of head and neck melanoma. Otolaryngol Head Neck Surg 2001; 125: 213-20.
12. 18FDG PET imaging versus sentinel node detection. The Oncologist 2002; 7: 271-8.
13. 99m Tc-MIBI scintigraphy. Melanoma Res 1998; 8: 355-60.
14. 99m Tc-MIBI en pacientes con melanoma. Alasbimn Journal 1998. Available at: http://www.alasbimnjournal.cl/revistas/1/ melanoma.htm. Accessed March 6, 2003.
15. Soler C, Perrot JL, Thiffet O, et al. The role of technetium-99m sestamibi single photon emission tomography in the follow-up of malignant melanoma and the detection of lymph node metastases. Eur J Nucl Med 1997; 24: 1522-5.
16. Augusseau-Caillot A, Soler C, Teyssier F, et al. Interest of PS100 assay when 99mTc sestamibi scintigraphy failed to identify lymph node metastases of melanoma. Eur J Dermatol 2001; 11: 432-5.
17. Balch CM, Buzaid AC, Soong SJ, et al Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
18. Thompson JF, Hunt JA, Culjak G, et al. Popliteal lymph node metastasis from primary cutaneous melanoma. Eur J Surg Oncol 2000; 26: 172-6.
19. WHO declares lymphatic mapping to be the standard of care for melanoma. Oncology 1999; 13: 288.
20. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: Controversy despite widespread agreement. J Clin Oncol 2001; 19: 2851-5.
21. Wrone DA, Tanabe KK, Cosimi AB, et al. Lymphedema after sentinel lymph node biopsy for cutaneous melanoma: A report of 5 cases. Arch Dermatol 2000; 136: 511-4.
22. Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy - a common event. Surgery 2001; 130: 439-42.
23. Vuylsteke RJ, van Leeuwen PA, Muller MG, et al. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 2003; 21: 1057-65.
24. Jansen L, Nieweg OE, Peterse JL, et al. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87: 484-9.
25. Martínez MA, Alonso O, Delgado LB, et al. Cutaneous malignant melanoma: scintigraphic detection of recurrent disease with Tc-99m MIBI. Eur J Dermatol 1997; 7: 433-5.
26. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. A multicenter trial. Ann Surg 1999; 230: 453-65.
27. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7: 469-74.
28. Lens MB, Dawes M, Newton-Bishop JA, Goodacre T. Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 2002; 39: 1223-7.
29. Essner R, Chung MH, Bleicher R, et al. Prognostic implications of thick (> = 4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol 2002; 9: 754-61.
30. Thompson JF, Shaw H. The prognosis of potients with thick primary melanomas: Is regional lymph node status relevant, and does removing positive regional nodes influence outcome ? Ann Surg Oncol 2002; 9: 719-22.
31. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I): mitochondrial plasma membrane potential dependence. Circulation 1990; 82: 1826-38.
32. Chen LB. Mitochondrial membrane potentials in lung cells. Annu Rev Cell Biol 1988; 4: 155-81.
33. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12: 450-8.
34. Molinari A, Calcabrini A, Meschini S, et al. Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells. Int J Cancer 1998; 75: 885-93.
35. Helmbach H, Sinha P, Schadendorf D. Human melanoma: drug resistance. Recent Results Cancer Res 2003; 161: 93-110.